Communication, Dissemination-smes engadgement, Medical technologies innovaton hub
CEBR is a membership-driven network of life science clusters and regional ecosystems across Europe, representing over 40 subscription members and hundreds of cluster partners across the world. Together, we represent and support a critical mass of SMEs, and hundreds of universities and research centres.
Oru main objectives are:
Technology assessment, Manufacturing, Medical technologies innovation hub, Dissemination-smes engagement
At INL – International Iberian Nanotechnology Laboratory, located in Braga (North of Portugal), scientists and engineers from all over the world work in a highly interdisciplinary environment and strive to make INL become a world-wide hub for the deployment of Nanotechnology addressing society’s grand challenges.
The INL was founded by the governments of Portugal and Spain under an international legal framework to perform interdisciplinary research, deploy and articulate nanotechnology for the benefit of society.
The research programme comprises four strategic fields of application of nanoscience and nanotechnology: Food and Environment monitoring, ICT, Renewable Energy and Health.
The full-fledged nanotechnology laboratory enables leading research of the highest international standard.
Roles: Clinical research, Medical technologies innovaton hub, Preclinical research, Characterization Contact: Pedro Silva (Technology Transfer Director)
The Instituto de Medicina Molecular João Lobo Antunes (IMM) is a private non-profit research institute that offers a vibrant scientific environment to nurture innovative ideas in basic, translational and clinical biomedical research in oncology, neurology, immunology and infection. IMM was created in 2002 and since then its strategy has been defined by the promotion of excellence, leveraged by high-quality human resources (currently 680 people work at IMM), state-of-the-art infrastructures and knowledge transfer to the society. IMM combines scientific excellence with dedicated support infrastructures to bring discoveries into clinical practice. Its facilities are equipped with state-of-the-art technology and dedicated staff, and include a biobank, a biosafety level 3 laboratory, zebrafish, insect and rodent facilities, flow cytometry, bioimaging, histology and comparative pathology, and fully equipped labs for chemical biology, pharmaceutical biotechnology, molecular and cell biology.
BIOKERALTY Research Institute AIE was constituted in 2006 with the aim of gathering the R&D activities in new medicines of the pharmaceutical Praxis Group, established in Vitoria (Spain).
The company is mainly devoted to the R&D activities in the field of APIs (Active Pharmaceutical Ingredients) obtained from biotechnology and biochemistry processes. One of its main strategic lines is focused on regenerative medicine for the treatment of chronic wounds.
BIOKERALTY is also highly active in R&D for the development of novel therapeutic alternatives for cancer and rare genetic diseases, using nanotechnology and biological molecules like proteins and peptides. Moreover, is also working in controlled release systems through microparticles and other nanoparticles (Solid Lipid Nanoparticles, Magnetic Nanoparticles, Lipid Nanovesicles), which improve therapeutic action of APIS and allow protection of biological molecules and targeting, imaging and future theragnostic of different diseases including cancer.
Since November 2018, BIOKERALTY is the R&D unit of the Keralty group, which is a multinational business group offering integrated health solutions across the health sector, providing both health care financing and health care delivery itself. Keralty also includes educational and socially focused organizations that complement its world of health mission.
Since, Keralty is devoted to the health and well-being of its members, patients and communities, BIOKERALTY will focus on the research of health technologies to elevate the state of health care in the countries where Keralty operates through technological, social and organizational innovation while generating employment, wealth and quality of life.
TECNALIA RESEARCH & INNOVATION (www.tecnalia.com) is a private, independent, non profit applied research center of international excellence. Legally a Foundation, Tecnalia is the leading private and independent research and technology organisation in Spain and one of the largest in Europe, employing around 1,445 people (225 PhDs) and with income of 108 Million € in 2018.
TECNALIA is committed to generate major impacts in economic terms, by means of innovation and technological development, addressed by 6 business divisions covering the economic sectors of Energy, Environment, Industry, Transport, Construction, Health and ICT. TECNALIA has been granted 396 patents and promoted more than 30 spin-off companies.
TECNALIA is a key agent in the ERA – European Research Area. TECNALIA actively participates in the governing bodies of several European Technology Platforms, PPPs and JTIs (EEB, FOF, SPIRE, ARTEMIS…). In FP7 activity TECNALIA had position 11th among RTOs and 23rd in absolute, according to the EC’s 7th FP7 Monitoring Report (Final), since we partnered in 377 projects, coordinating 81 of them; in H2020 TECNALIA is similarly active and participates in 228 projects, coordinating 47 of them, up to the end of December 2018. TECNALIA is a member of EARTO and of EUROTECH, linking together the most important RTOs in Europe.
The current proposal will be mainly carried out by the Biomaterials area of the Health Division.The group, has four main research fields: a) Synthesis and processing of biomaterials, b)surface modification of biomaterials, surface functionalization c)biocompatibility and toxicity testing (in vitro and in vivo) and d) Hybrid systems for biomaterials and medical devices (controlled drug release, lab-on chip, sensorized implants).It also offers technical services for biological evaluation, ISO certification, CE marking, cell-based assays and (nano)toxicology.
CNRS is a public funded research organization under the administrative authority of the French Ministry of Research. CNRS research laboratories are located throughout France, and employ a large body of tenured researchers, engineers and support staff. The Centre Interdisciplinaire de Nanoscience de Marseille (CINaM) is one of CNRS joint research units and specialized in multidisciplinary study on nanoscience and nanomaterials with state-of-art equipment. In particular, CINaM has all the expertise, know-how and infrastructure for the design, synthesis and characterization of functional dendrimers for biomedical applications including the delivery of small molecular drugs, bio-therapeutics and imaging agents as well as medical devices for diseases’ treatment and diagnosis. In addition, CINaM is specialized in fabrication of lipid bilayer – solid support, surface bio-nano-functionalization and membrane/cell adhesion, which will also contribute to the current proposal.
SINTEF is a non-profit independent research organization, and with approx. 20000 employees one of the largest in Europe. SINTEF performs contract research and development for a wide range of both Norwegian and international industry customers and participates as a research partner in publicly funded research projects, both at the national and to a large degree at the EU level. Annual revenues for SINTEF is more than 300 M€.
The Department of Biotechnology and Nanomedicine is participating in SAFE-N-MEDTECH with its extensive experience and significant ongoing project activity on synthesis and characterisation of nanomedicines. The Department is a core partner and assay group leader in EUNCL. State-of-the art instrumentation is available for physicochemical and chemical analyses, as well as high-throughput advanced in vitro analyses, both 2D and 3D cell-based assays. Analytical facilities and competence are also widely used for classical (i.e. on-material-related) pharmaceutical, small molecule and protein analyses. Also, the department has high competence in biotechnological processes, molecular genetics, bioinformatics and translation from lab to pilot scale
The Institute of Physical Chemistry “Ilie Murgulescu” of the Romanian Academy (www.icf.ro) was founded in 1963 by Academician Ilie Murgulescu who is also the founder of the modern school of physical chemistry at the University of Bucharest. At present, IPC stands as a unit of complex research that may approach a wide spectrum of basic and advanced problems of physical chemistry including quantum chemistry and molecular structure, chemical thermodynamics, chemical kinetics, surface chemistry and catalysis, electrochemistry and corrosion, oxide compounds and materials science, colloidal chemistry and coordination chemistry. The research activity in IPC is developed over ten programs, undertaken in 8 laboratories (one for each research area presented above) and 2 working groups for surface, interface and thin film analysis by X-ray photoelectron spectroscopy (XPS), and for high performance computing in materials science.
The research group involved in the project comes from The Laboratory of Chemical Thermodynamics which is a leading laboratory for basic and applied thermodynamic research, the scientific team leader being Dr. Speranta Tanasescu. She is Senior Researcher I and Ph.D. Supervisor. The research team is composed of three senior scientists and eight junior scientists. The members of the research group have an extensive experience in the research work of physical chemistry and related interdisciplinary fields. They are drawn from chemistry, biochemistry, materials and engineering backgrounds; especially the senior researchers have significant cross-disciplinary practice. Also there is a good experience of successful prior cooperation within the international (HORIZON2020, FP7, FP6, COST, SCOPES, DOE, POS-CCE), national R&D programs (Partnership-Program, CEEX, CNCSIS, Romanian Academy Grants etc.), bilateral and inter-academic cooperation. The research results have been published in important international refereed journals, books and have been communicated at different scientific national and international conferences. The original thermodynamic data were included in the Gmelin Handbuch der Anorganischen Chemie, „NIST”-Thermodynamic database, in the network of “Center for Rare Earth and Magnetics/Rare-earth Information Center” (CREM/RIC), “Bibliography on Thermodynamic Properties of Materials at High Temperatures”, “Rare-Earths” Japanese Journal, International Data Series-Selected Data, International Electronic Journal of Phys-Chem Data and were cited in PhD Theses and scientific papers.
Main areas of interest in the Laboratory of Chemical Thermodynamics:
(A). Nanosciences, Nanotechnologies, Materials and new Production Technologies
(B). Life sciences and biotechnology
Trinity College Dublin (TCD) is Ireland’s No.1 University – QS World University Ranking 2019; Trinity is ranked 104th in the World – QS World University Ranking 2018/19. TCD is one of Europe’s leading universities and member of the League of European Research Universities (LERU).
Under SAFE-N-MEDTECH, the TCD institute involved is the Trinity Translational Medicine Institute (TTMI) which partner with the St. James’s Hospital (SJH), the TCD university Hospital. TCD-SJH-TTMI account for the largest number of ongoing clinical trials in Ireland. TTMI specializes in the safe development of translational products including advanced nanomaterials, medical device or nanomedicine. TCD is also European leader in developing Responsible Research and Innovation (RRI) activities under the Science Gallery Dublin (TCD), the world first place in public engagement and scientific dissemination.
The Laboratory for the Biological Characterization of Advanced Materials (LBCAM) where Prof Prina-Mello is the lead director is located at TTMI, and in coordination with the Advanced Microscopy Laboratory (AML), is fully equipped for carrying out the main tasks proposed within the SAFE-N-MEDTECH project.
LBCAM is a member of several international organisations and project involved in the development of nanotechnology driven medical applications.
The University of Pavia is a University structured in 18 Departments distributed in the two locations of Pavia, the main one, and of Cremona. The Departments cover all the themes of the Life Sciences, Physical Sciences, Engineering and Social and Humanistic Sciences areas. The 18 Departments are supported by 20 interdepartmental centers whose aim is to develop and coordinate important interdisciplinary activities in basic or applied research. My research interests are focused on the design and development of medical devices and drug delivery systems intended for skin and tendon/ligament reparation and their chimico-physical and preclinical characterizations.
The Biomedical Research Networking Center (CIBER) is a Public Research Consortium created in 2006 under the leadership of the Carlos III Health Institute (ISCIII, the main Public Research Entity responsible of funding, managing and carrying out biomedical research in Spain), to promote research excellence in priority areas of Biomedicine and Health Science.
The CIBER-BBN (www.ciber-bbn.es) is the research center devoted to the study of Bioengineering, Biomaterials and Nanomedicine. Organized in three research areas: i) Bioengineering & Medical Imaging includes research groups devoted to the studies of Multimodal Diagnosis and Intelligent Devices & Biomedical Systems, ii) the area of Biomaterials & Advanced Therapies including lines on Cell and Gene Therapy, Tissue Engineering and Prostheses and Implants, while iii) the area of Nanomedicine includes among their research groups those devoted to the study of in vitro diagnostics, Nanotherapeutics and nanosafety.
CIBER-BBN, employs nearly 110 researchers directly hired by CIBER and conduct their research at any of the 46 participating groups from 22 different host institutions, as well as more than 430 associate researchers, who although having a contract with the corresponding consortium institution they are considered as attached-to-CIBER staff. The CIBER-BBN brings together some of the main Spanish research groups in the fields of Bioengineering, Biomaterials and Nanomedicine, including both universities and hospitals and other technological or research centers. Its purpose is to conduct translational research and to transfer the results to industry.
The National Research Institute on Occupational Health in Norway is the authorities’ main advisor upon work environment and occupational health related issues. The institute has a strategic advisory role to the Labour and Petroleum Inspection Authorities. As a sector institute, our research contributes to requested, and needed, knowledge within the area of work environment and occupational health. Being a sector institute, we provide scientific and knowledge based support in order to contribute to a knowledge-based public administration within our sector.
We are over 120 employees who create, use and promote knowledge on occupational health.
Our interdisciplinary research environment consists of people with various professional backgrounds, such as medicine, physiology, chemistry, biology, psychology among others.
Annually, STAMI is involved in well over 60 research projects. These projects can for example be long-term research-projects and sub-projects, or shorter projects with a more practical base.
VITO is a leading, independent research organization that provides sustainable technological solutions to industry and public authorities. It also offers scientifically based advice and support in the research domains of energy, materials, chemistry, land use and health in order to stimulate sustainable development. The research focus of the Health department is in the field of sustainable health and disease prevention, aiming at safe, effective and/or personalized technological innovations for diagnostics.
Molecular Biosensing group (MBx) is an interdepartmental research group in the Departments of Biomedical Engineering and Applied Physics at TU/e. The group consists of students and staff with backgrounds in physics, chemistry and biomedical technologies.
MBx develops technologies to detect molecules with single-molecule resolution in complex biological matrices. The research leads to novel methods for molecular biosensing with applications in point-of-care diagnostics and patient monitoring. The group is core member of the Institute for Complex Molecular Systems (ICMS).
Helia Biomonitoring is a spin-off company of Eindhoven University of Technology. The BPM sensing technology (Biosensing based on Particle Mobility) was invented and developed by researchers and students. The technology is being further developed for applications in industry and healthcare.
Resonant Circuits Limited (RCL) was founded in 2009 as a medical technology based spin-out company from University College London (UCL) capturing expertise and knowledge within the field of magnetic hyperthermia and susceptometry. RCL provides bespoke high frequency magnetic hyperthermia and susceptometry applications to suit needs in the medical and commercial industries.
TECNOLOGIA NAVARRA DE NANOPRODUCTOS, S. L. (TECNAN) produces and commercializes new raw materials (high performance nanoparticles) for various industrial applications, as well as other ready to use products based on them, positioning itself as one of the suppliers more competitive at national and European level of these new materials.
The nanoparticles production method developed by TECNAN is highly flexible, which permits to produce very sophisticated particles,, regardless of their complexity, for instance europium-yttrium oxide for the photovoltaic sector.
Practicality, innovation and high technology have allowed us to produce and commercialize singular products that have achieved to position themselves as leaders in their respective application areas.
And as we are in constant evolution, , listening to our customers and analyzing trends, we continuously discover new applications and utilities of our products.
reenDecision (GD) is a spin-off company of University Ca’ Foscari of Venice (UNIVE). Its mission is to transfer to European consortia and the private sector knowledge and experience generated for over a decade of research and development of strategies, modelling tools and Decision Support Systems (DSS) for risk assessment and management of chemicals and new technologies (incl. nano(bio)technologies used in medicine).
The main activities of the company involve developing and testing of tools to support complex decision making in the environmental, health and safety areas, and facilitating their exploitation by stakeholders from industry, regulation, academia and the civil society. This includes the development of software-based DSS, such as the ones developed in the large-scale EU projects SUN, caLIBRAte, BIORIMA and REFINE.
GD offers to private and public clients advanced and highly qualified support in the science and technology sectors by providing tailored decision analytical methodologies and software solutions able to integrate data and experimental/modelling tools with stakeholder perspectives and needs in order to address our clients’ objectives in cost-effective manner.
At the core of our lab stands the mechanistic understanding of drug/therapeutics distribution in the human body with the overall objective of providing solutions for the current obstacles hindering effective theapies. Our research group focuses on multiple experimental and computational approaches with projects spanning from the identification of patient characteristics influencing drug efficacy and toxicity, management of complex clinical scenarios and enhancement of drug delivery through innovative advanced materials.
Based at the University of Liverpool our team consists of post-doctoral researchers, PhD and masters students with a range of backgrounds in pharmacology, chemistry, molecular and cellular biology. With collaborations on a national and international level with both academia and industry, we pride ourselves on the quality and diversity of our work and are continuously looking to develop new relationships.
University of Liverpool: The University of Liverpool has, since 1881, worked for the advancement of learning and ennoblement of life. This remains our mission today and will give focus to all our efforts in the coming years as we strive to achieve our ambitions and aspirations, tackle the grand challenges of the age and make our vision a reality. We have laid down this explicit challenge of where we want to be in 10 years’ time, and now we must be just as clear on how we will get there.
We start from a position of strength. As a connected, global University with multiple physical and virtual campuses – Liverpool, London, Suzhou, Singapore and online – our worldwide influence and impact is unrivalled in higher education. Over the next decade we will build on our internationally recognised strengths in research and scholarship and increase collaborative and inter-disciplinary working. We will continue to develop a high-quality environment in which to educate well-rounded, enquiring global citizens who connect and engage – through their learning, research, civic engagement and inter-cultural understanding – with the world’s most pressing problems. We will integrate teaching and research to ensure that we derive the maximum benefit from our rich environment of intellectual enquiry and challenge.
The University values diversity; we are an inclusive institution, committed to the provision of opportunity for those with the capacity to benefit as individuals but also as members of a wider community dedicated to a sustainable and just society. We will be guided by strong ethical principles and ensure that our values are embedded in our plans and actions.
We will commit to a culture of continuous improvement and collaborative working, ensuring that we encourage and value the contributions of staff and students to decision-making, and foster good governance through a culture of openness and transparency. We respect difference, but will look for consistency and sharing of good practice to ensure that fairness and equality of opportunity inform our organisational structures and processes.
We will be confident and ambitious as we face future challenges, nurturing all our staff and supporting their personal and professional development in an environment of constant change. We will acknowledge and reward contributions to the achievement of the highest possible standards in every aspect of our work.
Our educational offer and world-leading research will be recognised regionally, nationally and internationally as distinctively collaborative. We place the utmost value on partnership working and we will continue to shape a robust network of education and industry alliances, forging productive relationships worldwide, building capacity and advancing knowledge.
Hubei Gedian Humanwell Pharmaceutical Co., Ltd. (here after referred as “Gedian Humanwell”) is one of the subsidiaries of Humanwell Healthcare group, which is now an international corporation with strong presence in Asia and North America. As an outstanding representative of Chinese pharmaceutical enterprise, Gedian Humanwell is highly innovative and dynamic. Its main business spans across R&D, manufacture and marketing of Active Pharmaceutical Ingredient (API), Finish Dosage Formulation (FDF) and pharmaceutical excipients. It strives to be a global fully integrated healthcare solution provider in the areas of women health and bio-products. Increasing international collaborative projects have been developed in Gedian Humanwell, with the aim to achieving the global objectives for the pharmaceutical development and contributing to the human well-being.
We are a value focused health company consisting of health insurance, health services and hospital and provider health care delivery organizations. Keralty also has educational institutions and socially focused companies that complete the “world of health” that we are offering society.
We are a group committed to the health of our members, keeping them healthy, focusing on prevention and the identification and management of health risks and diseases. We are leaders in comprehensive health services in the countries where we are present, being recognized for our humane, scientific, technical and ethical focus.
Welcome to CIBBIM-Nanomedicine. A comprehensive multidisciplinary Clinical Nanomedicine and Advanced Therapies Research Center. Created by the Catalan Health Department in 1995, we are part of the Vall d’Hebron University Hospital, the largest hospital complex in Catalonia and one of the largest in Spain , and of its research Institute –Institut de Recerca Vall d’Hebron (VHIR).
Our aim is to provide new treatments and diagnostics addressed to unmet clinical needs for the benefit of patients and society. For this, we have a full developed Research Program based on Advanced Therapies (ATMP) and Nanotechnology for Biomedical applications in human diseases.
Our main interests are the identification of new therapeutic targets, and the development of targeted and non-targeted drug delivery systems, new diagnostic biosensors and imaging tools, advanced cell therapies and tissue based regenerative medicine. In addition, we have fully dedicated certified facilities (ISO9001:2015) to ensure adequate proof-of-concept validation and preclinical studies, in which animal models are used for addressing the efficacy and preclinical toxicity of new nanomedicines and ATMP.
MARACA International bvba is a Belgian consulting company providing service excellence for Regulatory, Quality, Clinical and Medical Affairs assignments. This at Medical Device, IVD and pharma companies. Clinical laboratories, notified bodies and governmental agencies. These services support your product registrations in Europe under the MDD, IVDD, MDR and IVDR regulations. In the USA, our services support your submissions to the FDA.
Our services include training, Quality System management, risk management, development of Design Dossiers and Technical files, registration of devices, clinical evaluation reports, scientific validity reports and post-market follow-up plans and reports.